sglt2 inhibitors and glp 1 agonist GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Cardiovascular benefits of SGLT2 inhibitors
Description
Population-based cohort study
Not on current evidence
Contemporary pharmacological treatment and management of heart failure
R.ChahalP
An important feature of GLP-1 RA use in type 2 diabetes is weight loss, which reduces insulin resistance and typically reaches a plateau after around 6 months of treatment
Participants were asked about the education they received from healthcare providers during prescription and the level of satisfaction with that information
